Study ID: COG ACNS1022

A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas


This purpose of this study is to compare the response rate of pediatric patients with recurrent, refractory or progressive juvenile pilocytic astrocytomas and optic pathway gliomas who are treated with lenalidomide. The study will compare the study participant┬┐s response to either high-dose or low-dose treatment plan. The treatment participants will received is based on chance or a randomization process. Regimen A is the low-dose (20 mg/m2/dose) lenalidomide, and Regimen B is the high-dose (115 mg/m2/dose) lenalidomide.

Fargo Region, Sioux Falls Region
Principal Investigator:
Kayelyn Wagner, MD,Samuel Anim, MD
CNS (Brain Tumors)
Phase II


Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list